Differential and tumor-specific expression of CD160 in B-cell malignancies.

CD160 is a human natural killer (NK)-cell-activating receptor that is also expressed on T-cell subsets. In the present study, we examined 811 consecutive cases of B-cell lymphoproliferative disorders (B-LPDs), and demonstrated CD160 expression in 98% (590 of 600) of chronic lymphocytic leukemia (CLL) cases, 100% (32 of 32) of hairy cell leukemia (HCL) cases, 15% (5 of 34) of mantle cell lymphoma (MCL) in the leukemic phase, and 16% (23 of 145) of other B-LPD cases. CD160 transcript and protein were absent in the normal B-cell hierarchy, from stem cells, B-cell precursors, maturing B cells in the germinal center, and circulating B cells, including CD5(+)CD19(+) B1 cells in umbilical cord. CD160 positivity was significantly higher in CLL and HCL in terms of percentage (65.9% and 67.8%, respectively, P < .0001) and median fluorescence intensity (552 and 857, respectively, P < .0001) compared with all other B-LPD cases. Lymph node CLL samples were also CD160(+). Using the disease-specific expression of CD5, CD23, and CD160, a score of 3 characterized CLL (diagnostic odds ratio, 1430); a score of 0 excluded CLL, MCL, and HCL; and the CD23/CD5 ratio differentiated CLL from leukemic CD23(+) MCL. In the B-cell lineage, CD160 is a tumor-specific antigen known to mediate cellular activation signals in CLL, and is a novel target for therapeutic manipulation and monitoring of minimal residual disease.

[1]  L. Reiniger,et al.  ROR1 expression is not a unique marker of CLL , 2011, Hematological oncology.

[2]  Thomas M. Schmitt,et al.  The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. , 2010, Blood.

[3]  J. Gribben,et al.  CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. , 2010, Blood.

[4]  A. Chiarenza,et al.  CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. , 2009, Leukemia research.

[5]  G. Freeman,et al.  The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T‐cell activation , 2009, Immunological reviews.

[6]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[7]  G. Freeman,et al.  CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator , 2008, Nature Immunology.

[8]  M. Čolović,et al.  Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters , 2008, Medical oncology.

[9]  M. Shabani,et al.  Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia , 2008, Leukemia & lymphoma.

[10]  S. Valitutti,et al.  CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment. , 2007, International immunology.

[11]  Judith E. Cartwright,et al.  Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. , 2006, Blood.

[12]  M. Chilosi,et al.  ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage , 2006, Leukemia.

[13]  A. Saven,et al.  Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  N. Kay,et al.  ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype , 2005, Leukemia.

[15]  P. Parham.  MHC class I molecules and kirs in human history, health and survival , 2005, Nature Reviews Immunology.

[16]  S. Cajal,et al.  Immunohistochemical analysis of ZAP‐70 expression in B‐cell lymphoid neoplasms , 2005, The Journal of pathology.

[17]  H. Nückel,et al.  HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. , 2005, Blood.

[18]  P. Le Bouteiller,et al.  Cutting Edge: Engagement of CD160 by its HLA-C Physiological Ligand Triggers a Unique Cytokine Profile Secretion in the Cytotoxic Peripheral Blood NK Cell Subset1 , 2004, The Journal of Immunology.

[19]  Xinyu Zhao,et al.  ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL. , 2004, American journal of clinical pathology.

[20]  L. Moretta,et al.  Unravelling natural killer cell function: triggering and inhibitory human NK receptors , 2004, The EMBO journal.

[21]  Kai Fu,et al.  CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases. , 2003, American journal of clinical pathology.

[22]  J. Eisenmann,et al.  Cell surface CD43 determination improves diagnostic precision in late B‐cell diseases , 2003, British journal of haematology.

[23]  F. Mami-Chouaib,et al.  Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Arthur Weiss,et al.  Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. , 2002, Blood.

[25]  M. Nikolova,et al.  BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression. , 2002, International immunology.

[26]  Ash A. Alizadeh,et al.  Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia , 2001, The Journal of experimental medicine.

[27]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[28]  A. Lagoo,et al.  Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma. , 2001, American journal of clinical pathology.

[29]  Adelheid Cerwenka,et al.  Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.

[30]  Eric O Long,et al.  Cutting Edge: Induction of IFN-γ Production but Not Cytotoxicity by the Killer Cell Ig-Like Receptor KIR2DL4 (CD158d) in Resting NK Cells , 2001, The Journal of Immunology.

[31]  A. Barclay,et al.  The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans , 2001, Immunology.

[32]  F. Ajchenbaum‐Cymbalista,et al.  Cyclin D1 overexpression allows identification of an aggressive subset of leukemic lymphoproliferative disorder , 1999, Leukemia.

[33]  A. Singer,et al.  ZAP-70 Protein Promotes Tyrosine Phosphorylation of T Cell Receptor Signaling Motifs (ITAMs) in Immature CD4+8+ Thymocytes with Limiting p56lck , 1999, The Journal of experimental medicine.

[34]  G. Freeman,et al.  Cutting edge: MHC class I triggering by a novel cell surface ligand costimulates proliferation of activated human T cells. , 1999, Journal of immunology.

[35]  D. Catovsky,et al.  Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). , 1997, American journal of clinical pathology.

[36]  T. Kurosaki,et al.  Distinct tyrosine phosphorylation sites in ZAP-70 mediate activation and negative regulation of antigen receptor function , 1996, Molecular and cellular biology.

[37]  D. Catovsky,et al.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. , 1994, Leukemia.

[38]  G. Pinkus,et al.  Distinction between small lymphocytic and mantle cell lymphoma by immunoreactivity for CD23. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[39]  G. Leca,et al.  Significant enlargement of a specific subset of CD3+CD8+ peripheral blood leukocytes mediating cytotoxic T-lymphocyte activity during human immunodeficiency virus infection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Leca,et al.  A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity , 1993, The Journal of experimental medicine.

[41]  Arthur Weiss,et al.  ZAP-70: A 70 kd protein-tyrosine kinase that associates with the TCR ζ chain , 1992, Cell.

[42]  G. Delespesse,et al.  Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression , 1992, The Journal of experimental medicine.

[43]  K. Sikora,et al.  Leukemia , 1984, British Journal of Cancer.

[44]  D. Campana.  ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells. , 2005, Haematologica.

[45]  V. Deneys,et al.  Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close: flow cytometric distinction by the use of CD20 and CD54 expression , 2002, Leukemia.

[46]  C W Turck,et al.  ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. , 1992, Cell.

[47]  R. Blumberg,et al.  Intestinal Intraepithelial Lymphocytes Member Expressed on NK Cells, CTL, and Cloning of BY55, a Novel Ig Superfamily , 2022 .